非小细胞肺癌脑转移及其原发肿瘤的 EGFR 和 HER-2 状态。

EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor.

机构信息

Department of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.

出版信息

Neoplasma. 2011;58(1):27-34. doi: 10.4149/neo_2011_01_27.

DOI:10.4149/neo_2011_01_27

Abstract

We investigated EGFR and HER-2 status in brain metastatic non-small cell lung cancer (NSCLC) and compared them to EGFR and HER-2 status of primary NSCLC. Evaluated were 66 cases of brain metastatic NSCLC, including 20 cases of corresponding primary NSCLC. HER-2 status was investigated by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), and EGFR status was evaluated by IHC. HER-2 overexpression and/or amplification was/were observed in three cases (4.5 %) of 66 cases of brain metastatic NSCLC, and 23 cases (34.8%) demonstrated EGFR overexpression. Among 20 cases of primary and corresponding metastatic NSCLC, one case showed HER-2 overexpression and amplification in both primary and metastatic tumor. On the other hand, EGFR overexpression was noted in four cases of primary NSCLC and nine cases of metastatic NSCLC. Five cases showed EGFR gain in metastatic NSCLC. Brain metastatic NSCLC demonstrated different expression patterns of the abovementioned biomarkers, particularly EGFR when compared to primary NSCLC. Therefore, HER-2 and EGFR status are suggested to be evaluated in brain metastatic NSCLC for targeted monotherapy.

摘要

我们研究了脑转移非小细胞肺癌（NSCLC）中的 EGFR 和 HER-2 状态，并将其与原发性 NSCLC 的 EGFR 和 HER-2 状态进行了比较。评估了 66 例脑转移 NSCLC，包括 20 例相应的原发性 NSCLC。HER-2 状态通过免疫组织化学（IHC）和荧光原位杂交（FISH）进行检测，EGFR 状态通过 IHC 进行评估。在 66 例脑转移 NSCLC 中，有 3 例（4.5%）出现 HER-2 过表达和/或扩增，23 例（34.8%）显示 EGFR 过表达。在 20 例原发性和相应的转移性 NSCLC 中，有 1 例在原发性和转移性肿瘤中均出现 HER-2 过表达和扩增。另一方面，在 4 例原发性 NSCLC 和 9 例转移性 NSCLC 中观察到 EGFR 过表达。在转移性 NSCLC 中有 5 例出现 EGFR 获得。与原发性 NSCLC 相比，脑转移 NSCLC 上述生物标志物的表达模式不同，尤其是 EGFR。因此，建议对脑转移 NSCLC 进行 HER-2 和 EGFR 状态评估，以进行靶向单药治疗。